ES2055902T3 - Composiciones farmaceuticas de proteinas activadoras del plasminogeno. - Google Patents

Composiciones farmaceuticas de proteinas activadoras del plasminogeno.

Info

Publication number
ES2055902T3
ES2055902T3 ES90903109T ES90903109T ES2055902T3 ES 2055902 T3 ES2055902 T3 ES 2055902T3 ES 90903109 T ES90903109 T ES 90903109T ES 90903109 T ES90903109 T ES 90903109T ES 2055902 T3 ES2055902 T3 ES 2055902T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
activating proteins
plasminogen activating
plasminogen
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90903109T
Other languages
English (en)
Inventor
Benjamin S Isaacs
Himakshi Middlesex Stree Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Application granted granted Critical
Publication of ES2055902T3 publication Critical patent/ES2055902T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PRESENTAN FORMULAS FARMACEUTICAS DE INYECCIONES DE BOLO INTRAVENOSAS QUE PROPORCIONAN DELTAFE1X EN CONCENTRACIONES RELATIVAMENTE ALTAS A BAJAS CONCENTRACIONES DE EXCIPIENTES.
ES90903109T 1989-01-27 1990-01-26 Composiciones farmaceuticas de proteinas activadoras del plasminogeno. Expired - Lifetime ES2055902T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/302,846 US4980165A (en) 1989-01-27 1989-01-27 Pharmaceutical formulations of plasminogen activator proteins

Publications (1)

Publication Number Publication Date
ES2055902T3 true ES2055902T3 (es) 1994-09-01

Family

ID=23169461

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90903109T Expired - Lifetime ES2055902T3 (es) 1989-01-27 1990-01-26 Composiciones farmaceuticas de proteinas activadoras del plasminogeno.

Country Status (9)

Country Link
US (1) US4980165A (es)
EP (1) EP0455725B1 (es)
JP (1) JP2636499B2 (es)
AT (1) ATE104863T1 (es)
CA (1) CA2045562A1 (es)
DE (1) DE69008513T2 (es)
DK (1) DK0455725T3 (es)
ES (1) ES2055902T3 (es)
WO (1) WO1990008557A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
JP2520975B2 (ja) * 1989-09-21 1996-07-31 三井東圧化学株式会社 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤
US5366730A (en) * 1989-12-20 1994-11-22 Boehringer Mannheim Gmbh Stabilized compositions having human tissue type plasminogen activator enzymatic activity
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
DE59204945D1 (de) * 1991-04-16 1996-02-15 Boehringer Mannheim Gmbh Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
DK0643772T3 (da) * 1992-06-03 1998-02-02 Genentech Inc Glycosyleringsvarianter af vævsplasminogenaktivator med forbedrede terapeutiske egenskaber
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
KR101443826B1 (ko) 2007-06-14 2014-09-23 가부시키가이샤 폴라 파마 의약조성물
DE102007057543A1 (de) * 2007-11-29 2009-06-04 Merck Patent Gmbh a-Aminosäurederivate zur Löslichkeitsverbesserung
CA2742817A1 (en) 2008-11-20 2010-05-27 Biogen Idec Ma Inc. Arginine inactivation of viruses
CA2905788C (en) * 2013-03-12 2022-08-16 Emily A. Stein Dental composition comprising chelator and base

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54147916A (en) * 1978-05-12 1979-11-19 Sumitomo Chem Co Ltd Preparation of urokinase injection
DE3203775A1 (de) * 1982-02-04 1983-08-11 Behringwerke Ag, 3550 Marburg Fibrinogenzubereitung, verfahen zu ihrer herstellungund ihre verwendung
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
AU569429B2 (en) * 1985-05-28 1988-01-28 Wellcome Foundation Limited, The Aqueous acidic tissue plasminogen activator parenternal formulation
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
AU606582B2 (en) * 1985-09-06 1991-02-14 Codon Methods for the recovery of tissue plasminogen activator
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US4857320A (en) * 1987-02-19 1989-08-15 Monsanto Company Method of enhancing the solubility of tissue plasminogen activator
DE3718889A1 (de) * 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator

Also Published As

Publication number Publication date
DE69008513T2 (de) 1994-11-24
DK0455725T3 (da) 1994-09-05
JPH04503070A (ja) 1992-06-04
ATE104863T1 (de) 1994-05-15
CA2045562A1 (en) 1990-07-28
EP0455725A1 (en) 1991-11-13
US4980165A (en) 1990-12-25
EP0455725B1 (en) 1994-04-27
JP2636499B2 (ja) 1997-07-30
WO1990008557A1 (en) 1990-08-09
DE69008513D1 (de) 1994-06-01

Similar Documents

Publication Publication Date Title
ES2055902T3 (es) Composiciones farmaceuticas de proteinas activadoras del plasminogeno.
SE8402560D0 (sv) Farmaceutisk komposition
FI863664A0 (fi) Emulsionskompositioner foer dosering av i vatten svaorloesliga joniserbara hydrofoba laekemedel.
MX171191B (es) Composiciones farmaceuticas de glipizida
FI863652A0 (fi) 7-isopropoxiisflavoninklusionskomplex bildat med cyklodextrin och ett foerfarande foer dess framstaellning.
UA41502C2 (uk) Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання
ES2119411T3 (es) Combinaciones de proteinas y anticoagulantes tromboliticamente activos, y usos de los mismos.
DE69521693D1 (de) Taxanderivate enthaltende arzneizubereitungen
TR199700574T1 (xx) Molek�ler �aperon �retiminin haz�rlanmas� i�in yararl� hidroksilamin t�revleri ve bu t�revlerin haz�rlanmas�.
KR890700359A (ko) 안정한 인터페론 복합체
NO952151D0 (no) Injiserbare, taxanderivat-baserte preparater
SE8600632D0 (sv) Novel pharmaceutical composition
ES2037136T3 (es) Procedimiento para la preparacion de una solucion con elevada actividad volumetrica de una proteina con actividad de activador de plasminogeno de tejidos (t-pa).
TR199800717T2 (xx) Amyotrofik lateral skleroz tedavisine y�nelik ila� haz�rlamak i�in
KR900700124A (ko) 흑색종 치료용 il-2 및 dtic의 치료 조성물
DK148890D0 (da) Farmaceutisk praeparat
NO952900L (no) Materiale inneholdende tandospiron eller analoger derav
NO20042100L (no) Fremgangsmate for administrering av et tymosinalfa 1-peptid
ES2160582T3 (es) Capsula dura de ocfosfato de citarabina.
ATE130194T1 (de) Subkutane verabreichung des humanen choriongonadotropins.
SE8703788L (sv) Farmaceutiska kompositioner och anvendning av dessa
DE3679887D1 (de) Pharmazeutische zusammensetzung mit thrombolytischer wirkung.
BG100647A (en) Perenteral medicamentous form based on avremectine and ivermectine
BG28243A3 (en) Incecticide means
FR2453153A1 (fr) Nouveau derive de dehydroproline, sa preparation et son application comme medicament

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 455725

Country of ref document: ES